Tag: Clinical Trials

Now part of Rhelion Life Sciences, Canadian pharmaceutical developer Filament Health is supplying naturally derived psilocybin for clinical research worldwide, ...

US biotechnology company Enveric Biosciences has reported encouraging laboratory results for EB-003, an experimental psychiatric medicine designed to promote neuroplasticity ...

Early clinical data presented at the ECNP Congress show predictable psychedelic effects and measurable changes in brain activity, as the ...

The Canadian pharmaceutical manufacturer says it is supplying 26 Australian clinics with naturally derived psilocybin and is targeting further growth ...

The Australian-founded biotechnology company is progressing three investigational treatments, including a synthetic psilocybin therapy for generalised anxiety disorder, as its ...

Researchers at the University of Southern California will investigate whether mindfulness meditation can improve the effects of psilocybin-assisted therapy for ...

As psychedelic medicine moves towards pharmaceutical development, Incannex is attempting to take synthetic psilocybin through the clinical, regulatory and commercial ...

Melbourne-based Entropy Neurodynamics is advancing an intravenous psilocin programme spanning binge eating disorder, depression and other neuropsychiatric conditions, with recent ...

Optimi Health has completed production of a new batch of 5mg naturally derived psilocybin capsules, with the same batch set ...

For much of the past decade, the modern psychedelic renaissance has been accompanied by an unusually powerful media narrative. Drugs ...